{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:06:12Z","timestamp":1761102372672},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s12325-019-00962-1","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T20:47:18Z","timestamp":1557262038000},"page":"1549-1573","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in Clinical Cardiology 2018: A Summary of Key Clinical Trials"],"prefix":"10.1007","volume":"36","author":[{"given":"Katie","family":"Linden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conor","family":"McQuillan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian B. A.","family":"Menown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"issue":"26","key":"962_CR1","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1093\/eurheartj\/ehy275","volume":"39","author":"S Saito","year":"2018","unstructured":"Saito S, Krucoff MW, Nakamura S, et al. Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich\u2019s Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. Eur Heart J. 2018;39(26):2460\u20138.","journal-title":"Eur Heart J"},{"key":"962_CR2","unstructured":"Colombo A et al. One-year clinical outcomes of the bio-engineered COMBO stent: primary results from the 3614 all-comer patients in the COMBO Collaboration. Presented at American College of Cardiology Annual Scientific Sessions 2018. 11th March 2018; Orlando, FL."},{"key":"962_CR3","doi-asserted-by":"crossref","unstructured":"Kufner S, Joner M, Thannheimer A, et al. Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: results from the ISAR-TEST 4 randomized trial. Circulation. 2019;139;325\u201333.","DOI":"10.1161\/CIRCULATIONAHA.118.038065"},{"issue":"5","key":"962_CR4","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jcin.2016.12.002","volume":"10","author":"G El-Hayek","year":"2017","unstructured":"El-Hayek G, Bangalore S, Casso Dominguez A, et al. Meta-analysis of randomized clinical trials comparing biodegradable polymer drug-eluting stent to second-generation durable polymer drug-eluting stents. JACC Cardiovasc Interv. 2017;10(5):462\u201373.","journal-title":"JACC Cardiovasc Interv"},{"key":"962_CR5","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","volume":"373","author":"P Urban","year":"2015","unstructured":"Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373:2038\u201347.","journal-title":"N Engl J Med"},{"issue":"4","key":"962_CR6","doi-asserted-by":"publisher","first-page":"e418","DOI":"10.4244\/EIJ-D-18-00293","volume":"14","author":"J Lipiecki","year":"2018","unstructured":"Lipiecki J, Brunel P, Morice MC, et al. Biolimus A9 polymer-free coated stents in high bleeding risk patients undergoing complex PCI: evidence from the LEADERS FREE randomised clinical trial. EuroIntervention. 2018;14(4):e418\u201325.","journal-title":"EuroIntervention"},{"key":"962_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.118.037707","volume":"139","author":"R Rozemeijer","year":"2018","unstructured":"Rozemeijer R, Stein M, Voskuil M, et al. Randomized all-comers evaluation of a permanent polymer zotarolimus-eluting stent versus a polymer-free amphilimus-eluting stent:(ReCre8) a multicenter, non-inferiority trial. Circulation. 2018;139:67\u201377.","journal-title":"Circulation"},{"issue":"7","key":"962_CR8","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s12325-017-0560-5","volume":"34","author":"C McQuillan","year":"2017","unstructured":"McQuillan C, Gray A, Kearney A, et al. Advances in clinical cardiology 2017: a summary of key clinical trials. Adv Ther. 2017;34(7):1503\u201327.","journal-title":"Adv Ther"},{"key":"962_CR9","unstructured":"Aller D. TCT.18: Absorb stents are dead\u2014but what about BVS in general? \n                    https:\/\/www.cardiovascularbusiness.com\/topics\/coronary-intervention-surgery\/absorb-stents-dead-what-about-bvs-general\n                    \n                  . Accessed 18 Feb 2019."},{"key":"962_CR10","doi-asserted-by":"crossref","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC\/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87\u2013165.","DOI":"10.1093\/eurheartj\/ehy394"},{"key":"962_CR11","unstructured":"Byren RA. Intracoronary scaffold assessment a randomised evaluation of absorb in myocardial infarction (ISAR-Absorb MI) trial. Presented at European Society of Cardiology Congress 2018. 28th August 2018; Munich, Germany."},{"issue":"10157","key":"962_CR12","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S0140-6736(18)32283-9","volume":"392","author":"GW Stone","year":"2018","unstructured":"Stone GW, Ellis SG, Gori T, et al. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet. 2018;392(10157):1530\u201340.","journal-title":"Lancet"},{"key":"962_CR13","unstructured":"Smits PC. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent\u2014COMPARE-ABSORB. Presented at transcatheter cardiovascular therapeutics meeting 2018, 25th September 2018; San Diego, CA."},{"key":"962_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijcard.2017.12.053","volume":"255","author":"HM Garcia-Garcia","year":"2018","unstructured":"Garcia-Garcia HM, Haude M, Kuku K, et al. In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris\u2014DREAMS 2G) in de novo coronary lesions: insights from the BIOSOLVE-II first-in-man trial. Int J Cardiol. 2018;255:22\u20138.","journal-title":"Int J Cardiol"},{"key":"962_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.progpolymsci.2018.05.002","volume":"83","author":"S McMahon","year":"2018","unstructured":"McMahon S, Bertollo NO, Cearbhaill ED, et al. Bio-resorbable polymer stents: a review of material progress and prospects. Prog Polym Sci. 2018;83:79\u201396.","journal-title":"Prog Polym Sci"},{"key":"962_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.4244\/EIJV9I5A98","volume":"5","author":"R Waksman","year":"2013","unstructured":"Waksman R, Serra A, Loh JP, et al. Drug-coated balloons for de novo coronary lesions: results from the Valentines II trial. EuroIntervention. 2013;5:613\u20139.","journal-title":"EuroIntervention"},{"key":"962_CR17","unstructured":"Tuomas T, et al. Drug-eluting balloon for the treatment of de novo coronary artery lesions in patients with high bleeding risk\u2014a randomized controlled single-blind multicenter trial (DEBUT). Presented at EuroPCR annual scientific sessions 2018. 23rd May 2018; Paris, France."},{"issue":"10150","key":"962_CR18","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(18)31719-7","volume":"392","author":"RV Jeger","year":"2018","unstructured":"Jeger RV, Farah A, Ohlow MA, et al. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet. 2018;392(10150):849\u201356.","journal-title":"Lancet"},{"key":"962_CR19","unstructured":"Walsh S et al. The CONSISTENT CTO trial: CONventional antegrade vs Sub-Intimal Synergy sTENTing in chronic total occlusions. Presented at EuroPCR annual scientific sessions 2018. 24th May 2018; Paris, France."},{"issue":"3","key":"962_CR20","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1056\/NEJMoa1803538","volume":"379","author":"P Xaplanteris","year":"2018","unstructured":"Xaplanteris P, Fournier S, Pijls NH, et al. Five-year outcomes with PCI guided by fractional flow reserve. N Engl J Med. 2018;379(3):250\u20139.","journal-title":"N Engl J Med"},{"issue":"17","key":"962_CR21","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/CIRCULATIONAHA.118.033801","volume":"138","author":"R Al-Lamee","year":"2018","unstructured":"Al-Lamee R, Howard JP, Shun-Shin MJ, et al. Fractional flow reserve and instantaneous wave-free ratio as predictors of the placebo-controlled response to percutaneous coronary intervention in stable single-vessel coronary artery disease: physiology-stratified analysis of ORBITA. Circulation. 2018;138(17):1780\u201392.","journal-title":"Circulation"},{"issue":"13","key":"962_CR22","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1056\/NEJMoa1701067","volume":"376","author":"PC Smits","year":"2017","unstructured":"Smits PC, Abdel-Wahab M, Neumann FJ, et al. Fractional flow reserve\u2013guided multivessel angioplasty in myocardial infarction. N Engl J Med. 2017;376(13):1234\u201344.","journal-title":"N Engl J Med"},{"key":"962_CR23","unstructured":"Smits P. Two year results of COMPARE-ACUTE randomised trial of FFR-guided complete revascularization versus infarct artery only treatment in multivessel STEMI patients. Presented at EuroPCR Annual Scientific Sessions 2018. 23rd May 2018; Paris, France."},{"issue":"25","key":"962_CR24","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1710261","volume":"377","author":"H Thiele","year":"2017","unstructured":"Thiele H, Akin I, Sandri M, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med. 2017;377(25):2419\u201332.","journal-title":"N Engl J Med"},{"issue":"18","key":"962_CR25","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1056\/NEJMoa1808788","volume":"379","author":"H Thiele","year":"2018","unstructured":"Thiele H, Akin I, Sandri M, et al. One-year outcomes after PCI strategies in cardiogenic shock. N Engl J Med. 2018;379(18):1699\u2013710.","journal-title":"N Engl J Med"},{"key":"962_CR26","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1161\/CIRCULATIONAHA.118.037152","volume":"138","author":"KF Kofoed","year":"2018","unstructured":"Kofoed KF, Kelb\u00e6k H, Hansen PR, et al. Early versus standard care invasive examination and treatment of patients with non-st-segment elevation acute coronary syndrome: the VERDICT randomized controlled trial. Circulation. 2018;138:2741\u201350.","journal-title":"Circulation"},{"key":"962_CR27","unstructured":"Rapid Assessment of Potential Ischaemic Heart Disease With CTCA (RAPID-CTCA). \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02284191\n                    \n                  . Accessed 18 Feb 19."},{"key":"962_CR28","unstructured":"Fearon WF. FAST-FFR (FFRangio\u00a0accuracy versus standard FFR). Presented at transcatheter cardiovascular therapeutics meeting 2018, 24th September 2018; San Diego, CA."},{"issue":"(23 Part A)","key":"962_CR29","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1016\/j.jacc.2018.09.006","volume":"72","author":"TJ Ford","year":"2018","unstructured":"Ford TJ, Stanley B, Good R, et al. Stratified medical therapy using invasive coronary function testing in angina: the CorMicA trial. J Am Coll Cardiol. 2018;72((23 Part A)):2841\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"10150","key":"962_CR30","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/S0140-6736(18)31714-8","volume":"392","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Frigoli E, Leonardi S, et al. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet. 2018;392(10150):835\u201348.","journal-title":"Lancet"},{"key":"962_CR31","unstructured":"Waksman R. Assessment of coronary near-infrared spectroscopy imaging to detect vulnerable plaques and vulnerable patients. Presented at TCT 2018. September 24, 2018. San Diego, CA."},{"issue":"24","key":"962_CR32","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1161\/01.CIR.0000047200.36165.B8","volume":"106","author":"A Cribier","year":"2002","unstructured":"Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis\u2014first human case description. Circulation. 2002;106(24):3006\u20138.","journal-title":"Circulation"},{"issue":"36","key":"962_CR33","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","volume":"38","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC\/EACTS Guidelines for the management of valvular heart disease The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;38(36):2739.","journal-title":"Eur Heart J"},{"issue":"17","key":"962_CR34","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1514616","volume":"374","author":"MB Leon","year":"2016","unstructured":"Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374(17):1609\u201320.","journal-title":"N Engl J Med"},{"key":"962_CR35","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1700456","volume":"376","author":"MJ Reardon","year":"2017","unstructured":"Reardon MJ, Van Mieghem NM, Pompa JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376:1321\u201331.","journal-title":"N Engl J Med"},{"key":"962_CR36","unstructured":"Thyregod HGH, editor. Five-year outcomes from the all-comers nordic aortic valve intervention randomized clinical trial in patients with severe aortic valve stenosis. Presentation at American College of cardiology annual scientific sessions 2018; 2018 10th November 2018; Orlando, FL."},{"issue":"18","key":"962_CR37","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/j.jacc.2018.08.1033","volume":"72","author":"R Waksman","year":"2018","unstructured":"Waksman R, Rogers T, Torguson R, et al. Transcatheter aortic valve replacement in low-risk patients with symptomatic severe aortic stenosis. J Am Coll Cardiol. 2018;72(18):2095\u2013105.","journal-title":"J Am Coll Cardiol"},{"issue":"10087","key":"962_CR38","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/S0140-6736(17)30757-2","volume":"389","author":"T Chakravarty","year":"2017","unstructured":"Chakravarty T, Sondergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017;389(10087):2383\u201392.","journal-title":"Lancet"},{"key":"962_CR39","doi-asserted-by":"publisher","unstructured":"Bekeredjian R, Szabo G, Balaban U, et al. Patients at low surgical risk as defined by the Society of Thoracic Surgeons Score undergoing isolated interventional or surgical aortic valve implantation: in-hospital data and 1-year results from the German Aortic Valve Registry (GARY). Eur Heart J. 2018. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehy699\n                    \n                  .","DOI":"10.1093\/eurheartj\/ehy699"},{"key":"962_CR40","unstructured":"Didier R, Eltchaninoff H, Donzeau-Gouge P, et al. 5-year clinical outcame and valve durability after transcatheter aortic valve replacement in high-risk patients: the FRANCE-2 registry. Circulation. 2018. Presented at ESC Congress 2018. 29th August 2018. Munich, German."},{"issue":"8","key":"962_CR41","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jcin.2015.03.024","volume":"8","author":"M Barbanti","year":"2015","unstructured":"Barbanti M, Petronio AS, Ettori F, et al. 5-year outcomes after transcatheter aortic valve implantation with CoreValve prosthesis. JACC Cardiovasc Interv. 2015;8(8):1084\u201391.","journal-title":"JACC Cardiovasc Interv"},{"key":"962_CR42","unstructured":"Eltchaninoff H, editor. Clinical experiences and echo data from Rouen. Presented at transcatheter valve therapies. 17th June 2016; Chicago, IL."},{"issue":"25","key":"962_CR43","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1016\/j.jacc.2017.10.060","volume":"70","author":"H Reichenspurner","year":"2017","unstructured":"Reichenspurner H, Schaefer A, Schafer U, et al. Self-expanding transcatheter aortic valve system for symptomatic high-risk patients with severe aortic stenosis. J Am Coll Cardiol. 2017;70(25):3127\u201336.","journal-title":"J Am Coll Cardiol"},{"key":"962_CR44","unstructured":"Reichenspurner H, editor One-year outcomes of CENTERA-EU trial assessing a novel self-expanding transcatheter heart valve. Presented at Euro PCR 2018, 22nd May 2818; Paris, France."},{"key":"962_CR45","doi-asserted-by":"publisher","unstructured":"Sondergaard L, Rodes-Cabau J, Linke AH, et al. One-year outcomes with a self-expanding, repositonable transcatheter heart valve in severe aortic stenosis patients: PORTICO-I. J Am Coll Cardiol. 2018. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2018.09.014\n                    \n                  .","DOI":"10.1016\/j.jacc.2018.09.014"},{"issue":"22","key":"962_CR46","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/j.jcin.2018.07.032","volume":"11","author":"G Manoharan","year":"2018","unstructured":"Manoharan G, Van Mieghem NM, Windecker S. 1-year outcomes with the Evolut R self-expanding transcatheter aortic valve from the international FORWARD study. JACC Cardiovasc Interv. 2018;11(22):2326\u201334.","journal-title":"JACC Cardiovasc Interv"},{"key":"962_CR47","unstructured":"Thiele H, editor. A 2\u2009\u00d7\u20092 randomized trial of self-expandable vs balloon-expandable valves and general vs local anesthesia in patients undergoing transcatheter aortic valve implantation. Presented at transcatheter cardiovascular therapeutics meeting 2018, 23rd September 2018; San Diego, CA."},{"key":"962_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2019.01.073","author":"KB Allen","year":"2019","unstructured":"Allen KB, Chhatriwalla AK, Saxon JT, et al. Bioprosthetic valve fracture: technical insights from a multicenter study. J Thorac Cardiovasc Surg. 2019. \n                    https:\/\/doi.org\/10.1016\/j.jtcvs.2019.01.073\n                    \n                  .","journal-title":"J Thorac Cardiovasc Surg"},{"key":"962_CR49","unstructured":"Worhle J. ADVERTORIAL: Sentinel Cerebral Protection System provides reassurance to both physicians and patients. \n                    https:\/\/cardiovascularnews.com\/advertorial-sentinel-cerebral-protection-system-provides-reassurance-to-both-physicians-and-patients\/2018\n                    \n                  . Accessed 25 Nov 2018."},{"issue":"2","key":"962_CR50","doi-asserted-by":"publisher","first-page":"128","DOI":"10.15420\/icr.2017:19:2","volume":"12","author":"U Schafer","year":"2017","unstructured":"Schafer U. Safety and efficacy of protected cardiac intervention: clinical evidence for sentinel cerebral embolic protection. Interv Cardiol Rev. 2017;12(2):128\u201332.","journal-title":"Interv Cardiol Rev"},{"key":"962_CR51","unstructured":"Makker R. Presented at cardiovascular research technologies 2018. 3rd March 2018; Washington, DC."},{"key":"962_CR52","doi-asserted-by":"crossref","unstructured":"Overtchouk P, Guedeney P, Rouanet S, et al. Long-term mortality and early valve dysfunction according to anticoagulation use: the FRANCE-TAVI registry. J Am Coll Cardiol. 2019;73(1):13\u201321.","DOI":"10.1016\/j.jacc.2018.08.1045"},{"key":"962_CR53","unstructured":"Neale T. GALILEO trial of rivaroxaban after TAVR stopped early for harm. \n                    https:\/\/www.tctmd.com\/news\/galileo-trial-rivaroxaban-after-tavr-stopped-early-harm2018\n                    \n                  . Accessed 25 Nov 2018."},{"key":"962_CR54","unstructured":"Barbanti M. PCR LV 2018: early discharge feasible for unselected TAVI patients \n                    https:\/\/cardiovascularnews.com\/pcr-lv-2018-early-discharge-feasible-for-unselected-tavi-patients\/2018\n                    \n                  . Accesssed 25 Nov 2018."},{"issue":"15","key":"962_CR55","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa1009355","volume":"364","author":"T Feldman","year":"2011","unstructured":"Feldman T, Foster E, Glower DG, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364(15):1395\u2013406.","journal-title":"N Engl J Med"},{"key":"962_CR56","doi-asserted-by":"crossref","unstructured":"Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2108;379(24):2297\u20132306.","DOI":"10.1056\/NEJMoa1805374"},{"key":"962_CR57","doi-asserted-by":"crossref","unstructured":"Stone G, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379(24):2307\u201318.","DOI":"10.1056\/NEJMoa1806640"},{"key":"962_CR58","unstructured":"Wood S. COAPT: MitraClip reduces repeat hospitalizations, mortality in functional MR patients with severe HF. \n                    https:\/\/www.tctmd.com\/news\/coapt-mitraclip-reduces-repeat-hospitalizations-mortality-functional-mr-patients-severe-hf2018\n                    \n                  . Accessed 25 Nov 2018."},{"key":"962_CR59","unstructured":"RESHAPE-HF2 investigators and sponsors. A clinical evaluation of the safety and effectiveness of the MitraClip system in the treatment of clinically significant functional mitral regurgitation (Reshape-HF2). \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02444338\n                    \n                  . Accessed 25 Nov 2018."},{"key":"962_CR60","unstructured":"Latib A, editor. 6\u00a0month results from TRI-REPAIR. Presented at London Valve PCR 2018. 9th September 2018; London, England."},{"key":"962_CR61","doi-asserted-by":"crossref","unstructured":"Iverson K, Ihlemann N, Gill SU, et al. Artial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380(5):415\u201324.","DOI":"10.1056\/NEJMoa1808312"},{"issue":"41","key":"962_CR62","first-page":"2873-926","volume":"35","author":"R Erbel","year":"2014","unstructured":"Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J. 2014;35(41):2873-296.","journal-title":"Eur Heart J"},{"key":"962_CR63","unstructured":"Mullen M, editor. AIMS\u2014Aortic Irbesartan Marfan Study. Presented at European Society of Cardiology Congress 2018. 28th August 2018; Munich, Germany."},{"key":"962_CR64","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"issue":"23","key":"962_CR65","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","volume":"71","author":"M Kosiborod","year":"2018","unstructured":"Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs the CVD-REAL 2 study. J Am Coll Cardiol. 2018;71(23):2628\u201339.","journal-title":"J Am Coll Cardiol"},{"key":"962_CR66","doi-asserted-by":"crossref","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","DOI":"10.1056\/NEJMoa1812389"},{"issue":"5","key":"962_CR67","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","volume":"138","author":"K R\u00e5dholm","year":"2018","unstructured":"R\u00e5dholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation. 2018;138(5):458\u201368.","journal-title":"Circulation"},{"key":"962_CR68","unstructured":"Kumbhani D. EMPA-HEART Cardiolink-6\u2014EMPA-HEART. Presented at American Heart Association Annual Scientific Sessions 2018. 11th November 2018; Chicago, IL."},{"key":"962_CR69","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317\u201326.","journal-title":"N Engl J Med"},{"key":"962_CR70","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327\u201335.","journal-title":"N Engl J Med"},{"issue":"1","key":"962_CR71","first-page":"8","volume":"6","author":"JJV McMurray","year":"2018","unstructured":"McMurray JJV, Ponikowski P, Bolli GB, et al. Effects of vildagliptin on ventricular function in patients with type 2 diabetes\u00a0mellitus and heart failure: a randomized placebo-controlled trial. J Am Coll Cardiol Heart Fail. 2018;6(1):8\u201317.","journal-title":"J Am Coll Cardiol Heart Fail"},{"issue":"14","key":"962_CR72","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1056\/NEJMoa1717250","volume":"378","author":"RG Victor","year":"2018","unstructured":"Victor RG, Lynch K, Li N, et al. A cluster-randomized trial of blood-pressure reduction in black barbershops. N Engl J Med. 2018;378(14):1291\u2013301.","journal-title":"N Engl J Med"},{"issue":"6","key":"962_CR73","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jama.2018.10359","volume":"320","author":"R Webster","year":"2018","unstructured":"Webster R, Salam A, Silva HA, et al. Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka a randomized clinical trial. J Am Med Assoc. 2018;320(6):566\u201379.","journal-title":"J Am Med Assoc"},{"issue":"10137","key":"962_CR74","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","volume":"391","author":"DE Kandzari","year":"2018","unstructured":"Kandzari DE, Bohm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346\u201355.","journal-title":"Lancet"},{"issue":"10153","key":"962_CR75","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(18)31776-8","volume":"392","author":"A Gupta","year":"2018","unstructured":"Gupta A, Mackay J, Whitehouse A, et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018;392(10153):1127\u201337.","journal-title":"Lancet"},{"issue":"10152","key":"962_CR76","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","volume":"392","author":"JM Gaziano","year":"2018","unstructured":"Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036\u201346.","journal-title":"Lancet"},{"issue":"16","key":"962_CR77","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","volume":"379","author":"L Bowman","year":"2018","unstructured":"Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529\u201339.","journal-title":"N Engl J Med"},{"key":"962_CR78","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322.","journal-title":"N Engl J Med"},{"key":"962_CR79","doi-asserted-by":"crossref","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u20132107.","DOI":"10.1056\/NEJMoa1801174"},{"issue":"16","key":"962_CR80","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","volume":"379","author":"L Bowman","year":"2018","unstructured":"Bowman L, Mafham M, Wallendszus K, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379(16):1540\u201350.","journal-title":"N Engl J Med"},{"key":"962_CR81","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","volume":"369","author":"M Yokoyama","year":"2007","unstructured":"Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090\u20138.","journal-title":"Lancet"},{"key":"962_CR82","doi-asserted-by":"crossref","unstructured":"Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322.","DOI":"10.1056\/NEJMoa1812792"},{"issue":"12","key":"962_CR83","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1808721","volume":"379","author":"EA Bohula","year":"2018","unstructured":"Bohula EA, Wiviott SD, McGuire DK, et al. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med. 2018;379(12):1107\u201317.","journal-title":"N Engl J Med"},{"issue":"10","key":"962_CR84","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1805971","volume":"379","author":"DE Newby","year":"2018","unstructured":"Newby DE, Adamson PD, Berry C, et al. Coronary CT angiography and 5-year risk of myocardial infarction. N Engl J Med. 2018;379(10):924\u201333.","journal-title":"N Engl J Med"},{"issue":"12","key":"962_CR85","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med"},{"key":"962_CR86","doi-asserted-by":"crossref","unstructured":"Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotraxate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752\u201362.","DOI":"10.1056\/NEJMoa1809798"},{"issue":"1","key":"962_CR87","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/ejcts\/ezx334","volume":"53","author":"M Valgimigli","year":"2017","unstructured":"Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2017;53(1):34\u201378.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"10127","key":"962_CR88","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","volume":"391","author":"JY Hahn","year":"2018","unstructured":"Hahn JY, Song YB, Oh JH, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018;391(10127):1274\u201384.","journal-title":"Lancet"},{"issue":"10151","key":"962_CR89","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"P Vranckx","year":"2018","unstructured":"Vranckx P, Valgimigli M, J\u00fcni P, et al. Ticagrelor plus aspirin for 1\u00a0month, followed by ticagrelor monotherapy for 23\u00a0months vs aspirin plus clopidogrel or ticagrelor for 12\u00a0months, followed by aspirin monotherapy for 12\u00a0months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940\u20139.","journal-title":"Lancet"},{"issue":"6","key":"962_CR90","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1161\/01.CIR.0000137828.06205.87","volume":"110","author":"V Pasceri","year":"2004","unstructured":"Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) study. Circulation. 2004;110(6):674\u20138.","journal-title":"Circulation"},{"issue":"23","key":"962_CR91","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1016\/j.jacc.2009.07.005","volume":"54","author":"C Briguori","year":"2009","unstructured":"Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol. 2009;54(23):2157\u201363.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"962_CR92","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jama.2018.2444","volume":"319","author":"O Berwanger","year":"2018","unstructured":"Berwanger O, Santucci EV, de Andrade Jesu\u00edno I, et al. Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome: the SECURE-PCI randomized clinical trial. J Am Med Assoc. 2018;319(13):1331\u201340.","journal-title":"J Am Med Assoc"},{"issue":"10151","key":"962_CR93","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(18)31923-8","volume":"392","author":"AS Shah","year":"2018","unstructured":"Shah AS, Anand A, Strachan FE, et al. High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. Lancet. 2018;392(10151):919\u201328.","journal-title":"Lancet"},{"key":"962_CR94","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","volume":"127","author":"AL Dans","year":"2013","unstructured":"Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2013;127:634\u201340.","journal-title":"Circulation"},{"key":"962_CR95","doi-asserted-by":"crossref","unstructured":"Matsumura-Nakano Y, Shizuta S, Komasa A, et al. An open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond one year after coronary stent implantation: the OAC-ALONE study. Circulation. 2019;139:604\u201316.","DOI":"10.1161\/CIRCULATIONAHA.118.036768"},{"key":"962_CR96","unstructured":"Packer DL. Catheter ablation vs antiarrhythmic drug therapy in atrial fibrillation: the results of the CABANA multicenter international randomized clinical trial. Presented at Heart Rhythm Society 2018. 10th May 2018; Boston, MA."},{"key":"962_CR97","unstructured":"Poole JE. Recurrence of atrial arrhythmias in the catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation (CABANA) Trial. Presented at European Society of Cardiology Congress 2018. 26th August 2018; Munich, Germany."},{"key":"962_CR98","unstructured":"Connolly S. Interim report on the ANNEXA-4 study: andexanet for reversal of anticoagulation in factor Xa associated acute major bleeding. Presented at American College of Cardiology Scientific Sessions 2018. 12th March 2018; Orlando, FL."},{"issue":"32","key":"962_CR99","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1093\/eurheartj\/ehy148","volume":"39","author":"MD Ezekowitz","year":"2018","unstructured":"Ezekowitz MD, Pollack CV, Halperin JL, et al. Apixaban compared to heparin\/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018;39(32):2959\u201371.","journal-title":"Eur Heart J"},{"issue":"41","key":"962_CR100","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","volume":"36","author":"SG Priori","year":"2015","unstructured":"Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Eur Heart J. 2015;36(41):2793\u2013867.","journal-title":"Eur Heart J"},{"issue":"13","key":"962_CR101","first-page":"272","volume":"138","author":"SM Al-Khatib","year":"2017","unstructured":"Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2017;138(13):272\u2013391.","journal-title":"Circulation"},{"issue":"13","key":"962_CR102","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1056\/NEJMoa1800781","volume":"379","author":"JE Olgin","year":"2018","unstructured":"Olgin JE, Pletcher MJ, Vittinghoff E, et al. Wearable cardioverter-defibrillator after myocardial infarction. N Engl J Med. 2018;379(13):1205\u201315.","journal-title":"N Engl J Med"},{"key":"962_CR103","doi-asserted-by":"crossref","unstructured":"Zei PC, Mak R. Noninvasive stereotactic radioablation for ventricular tachycardia ENCORE-VT (EP-Guided Noninvasive Cardiac Radioablation): is the sequel as good as the original? Circulation. 2019;139;322\u20134.","DOI":"10.1161\/CIRCULATIONAHA.118.038285"},{"issue":"20","key":"962_CR104","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1016\/j.jacc.2018.02.048","volume":"71","author":"M Abdelrahman","year":"2018","unstructured":"Abdelrahman M, Subzposh FA, Beer D, et al. Clinical outcomes of his bundle pacing compared to right ventricular pacing. J Am Coll Cardiol. 2018;71(20):2319\u201330.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"962_CR105","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004.","journal-title":"N Engl J Med"},{"key":"962_CR106","doi-asserted-by":"crossref","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539\u201348.","DOI":"10.1056\/NEJMoa1812851"},{"issue":"15","key":"962_CR107","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.jacc.2017.08.010","volume":"70","author":"MM Givertz","year":"2017","unstructured":"Givertz MM, Stevenson LW, Costanzo MR, et al. Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2017;70(15):1875\u201386.","journal-title":"J Am Coll Cardiol"},{"key":"962_CR108","unstructured":"Abraham J. CardioMEMS. Presented at American College of Cardiology Annual Scientific Sessions 2018. 12th March 2018; Orlando, FL."},{"key":"962_CR109","unstructured":"Guide HF authors and sponsors. Hemodynamic-GUIDEd Management of Heart Failure (GUIDE-HF). \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03387813\n                    \n                  . Accessed 26 Nov 2018."},{"issue":"10152","key":"962_CR110","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S0140-6736(18)31880-4","volume":"392","author":"F Koehler","year":"2018","unstructured":"Koehler F, Koehler K, Deckwart O, et al. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet. 2018;392(10152):1047\u201357.","journal-title":"Lancet"},{"issue":"15","key":"962_CR111","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1056\/NEJMoa1800866","volume":"378","author":"MR Mehra","year":"2018","unstructured":"Mehra MR, Goldstein DJ, Uriel N, et al. Two-year outcomes with a magnetically levitated cardiac pump in heart failure. N Engl J Med. 2018;378(15):1386\u201395.","journal-title":"N Engl J Med"},{"key":"962_CR112","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","volume":"55","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55:213\u201320.","journal-title":"J Am Coll Cardiol"},{"key":"962_CR113","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981\u20138.","journal-title":"Circulation"},{"issue":"20","key":"962_CR114","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","volume":"71","author":"MS Avila","year":"2018","unstructured":"Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol. 2018;71(20):2281\u201390.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"962_CR115","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1056\/NEJMoa1808848","volume":"379","author":"F Zannad","year":"2018","unstructured":"Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med. 2018;379(14):1332\u201342.","journal-title":"N Engl J Med"},{"issue":"11","key":"962_CR116","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316.","journal-title":"N Engl J Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00962-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-00962-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00962-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T23:09:52Z","timestamp":1588720192000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-00962-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":116,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["962"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-00962-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,7]]},"assertion":[{"value":"29 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}